Sixteen Years After TRANSFER-AMI, Rural STEMI In-hospital Outcomes Remain Unchanged: Confronting the Pharmacoinvasive Paradox Authors: Amir Lofti, Aravdeep Jhand Published: 2026 Outcomes of patients presenting with ST-elevation myocardial infarction (STEMI) have improved dramatically over the past 3 decades, backed by numerous evidence-based interventions and the development of coordinated regional systems of care. Refinement of antithrombotic and antiplatelet therapy, adoption of radial access, and innovations in drug-eluting stents have substantially improved the survival in this critically ill patient population. Timely percutaneous coronary intervention (PCI) remains the cornerstone of management in STEMI with a goal of <90 minutes from point of first medical contact in PCI-capable centers and <120 minutes in the setting of transfers from non–PCI-capable hospitals. Despite advances in PCI, geographic disparities exist, and rural patients experience longer reperfusion times and lower rates of primary PCI compared with urban patients. The pharmacoinvasive (PI) strategy—fibrinolysis at a non–PCI-capable facility followed by prompt transfer for angiography—is the guideline-endorsed approach for rural STEMI patients who cannot undergo timely primary PCI, established by TRANSFER-AMI1 and reaffirmed in the 20132 and 2025 ACC/AHA guidelines.3 However, in this issue of JSCAI, Rothstein et al4 report that across 2 decades and 2228 consecutive patients managed with a PI strategy at a regional New England STEMI network, substantial improvements in care delivery were not accompanied by significant differences in in-hospital outcomes between eras: mortality was numerically higher in the modern era (2013 onward) than in the premodern era (5.2% vs 4.1%; P = .25), whereas major adverse cardiovascular events (MACE) and bleeding remained similar. What improved The care delivery advances are substantial. Door-to-needle time fell from 56 to 49 minutes, raising benchmark achievement from 25% to 42%. Full-dose tenecteplase became near universal, and preprocedural P2Y12 use rose from 59% to 84%, consistent with CLARITY-TIMI 28, which showed that adjunctive clopidogrel reduces the composite of cardiovascular death, recurrent myocardial infarction, and urgent revascularization.5 Radial access increased substantially, reflecting broader contemporary practice, although the randomized evidence most often cited in support of this shift was not derived specifically from fibrinolysis-treated PI cohorts.6,7 Most strikingly, door-to-transfer-to-device time was nearly halved, from 413 to 218 minutes, driven by routine immediate PCI on transfer. Hospital length-of-stay was also shortened from 4.1 to 3.2 days. What did not improve and why Three mechanisms may explain the lack of demonstrable outcome gains in terms of mortality and MACE. First, survivorship bias likely enriches the modern cohort: improved prehospital care allows patients who previously died before hospital arrival to be captured in the registry, and the rural emergency medical services network’s inability to transport refractory cardiac arrest patients may amplify this beyond urban settings. This may, therefore, reflect a sicker captured population rather than true deterioration. Second, in-hospital end points across hospitalizations averaging only a few days cannot detect longer-term reperfusion benefits, a pattern echoed in a 12-year Canadian STEMI registry showing improved process times without detectable in-hospital mortality benefit.8 Third, pandemic-related presentation delays in 2020 cannot be excluded as a late-period confounder. The study’s risk adjustment was limited, and residual confounding remains possible. A cautionary note on the stroke finding Ischemic stroke appeared reduced in the modern era (0.1% vs 1.4%; adjusted OR 13.8; 95% CI, 1.8-104.1; P = .01), but with only 1 event in the modern cohort, the confidence interval is wide, rendering the finding statistically fragile and mechanistically difficult to interpret. The larger rural–urban chasm Minhas et al9 have previously documented a local paradox. Rural hospitals report higher in-hospital mortality despite similar 30-day STEMI outcomes after comorbidity adjustment, underscoring the need for long-term end points. Rural patients remain underrepresented in contemporary STEMI trial enrollment. The Dartmouth-Hitchcock network, serving 1.5 million patients where 80% to 90% live beyond 120-minute PCI reach, represents one of the best-described rural STEMI systems in the United States; if 2 decades of systematic improvement have not moved in-hospital outcomes here, further process optimization by itself may be insufficient to close the gap. If anything, the persistence of this disparity despite genuine process gains implies that the limiting factor is not systems optimization—it is geography itself. The time required to transfer a rural patient to a PCI-capable hospital imposes a biological cost on the myocardium that no amount of protocol refinement can overcome. Fibrinolytic therapy, even when administered promptly and followed by an early invasive strategy, is simply not equivalent to primary PCI. What should come next Prospective registries with 30-day and 1-year follow-up are the most pressing need: current data cannot confirm that today’s process gains translate to durable benefit. Better PI vs primary PCI decision support is also required; modeling suggests PI may be preferred when transfer times are prolonged.10 Prehospital investment also merits attention: paramedic-administered fibrinolysis, enhanced field triage, and telemedicine linkage between rural emergency physicians and interventional cardiologists could compress first-medical-contact-to-device times in geographically isolated communities. Conclusions The process of STEMI management in rural settings has improved; the task of improving outcomes is ahead. The Dartmouth-Hitchcock STEMI network exemplifies what protocol-driven rural cardiovascular care can achieve, and the improvements documented by Rothstein et al are real and hard-won. However, 16 years after TRANSFER-AMI, in-hospital outcomes remain unchanged. This is not a failure of those who built this network but a reminder that rural STEMI care remains understudied and that long-term registries, prospective trials, and targeted policy investments are overdue. CRediT authorship contribution statement Amir Lofti: Conceptualization, Writing – original draft, Writing – review & editing. Aravdeep Jhand: Conceptualization, Writing – original draft, Writing – review & editing. Declaration of competing interest The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.